Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE  OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 Bellevue city ... hall of technology solutions for people with disabilities ... Hyatt Regency Bellevue. , The exhibit hall, ... on Saturday and Sunday, will feature leading manufacturers ... wheelchairs, communication devices, eyegaze technologies, computer applications, and ...
(Date:6/19/2013)... , June 19, 2013  U.S. Secretary of ... ceremony at which distinguished Syngenta  scientist Mary-Dell ... prestigious 2013 World Food Prize. The prize is the ... development by improving the quality, quantity or availability of ... two other laureates were recognized for "revolutionary biotechnology discoveries ...
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... plant, stool and other challenging microbial nucleic acid ... Protein Extraction Kit, for extraction of pure protein ... protein world coincides with the 20 th ... growing innovation capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ...
Breaking Biology Technology:City of Bellevue, Wash., Welcomes Assistive Technology Exhibit Hall 2Syngenta's Mary-Dell Chilton named 2013 World Food Prize laureate 2Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2
... today that,it received notice from Israel,s Chief Scientist,s Office ... D-Pharm,s R&D programs with a,total grant of up to ... PhD, CEO and President of D-Pharm, said "We are ... its firm support over the years,from the time of ...
... Researchers at The University of Manchester have used graphene ... and glimpse the foundations of the universe. , The ... by Professor Andre Geim, have found that the worlds ... which allows the direct determination of the fine structure ...
... includes refocusing of operations and workforce reduction, ... KERX ) today announced that it is ... burn rate and re-focus its,development efforts. The plan, ... Company,s pivotal SUN-MICRO Phase 3 clinical trial of ...
Cached Biology Technology:D-Pharm Secures Funding From Israel's Chief Scientist's Office 2Graphene gazing gives glimpse of foundations of universe 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 3Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 4
(Date:6/18/2013)... At Brandeis University, sophisticated computational models and advances ... the complex interplay between genomic data, virus structure ... critical for replication. , "We ... will help researchers alter virus assembly, leaving viruses ... first author of the scientific paper describing the ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... 18, 2013 The herbal extract of a yellow-flowered ... to increase the lifespan of fruit fly populations by ... researchers. , But it,s how Rhodiola ... that grabbed the attention of study leaders Mahtab Jafari ... works in a manner completely unrelated to dietary restriction ...
Breaking Biology News(10 mins):Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2
... New research from the University of Bristol shows that by ... wound cells, wounds can heal faster and reduce scarring. This ... for people who suffer organ tissue damage through illness or ... forms and cells underneath the wound start to repair the ...
... Scientists have pinpointed a set of common variations in ... in women who carry them. Some of these variations ... may help future studies examining whether lupus is more ... a new study. Also, the findings point to ...
... Minn. -- Featured articles from the January issue of ... on cancer, guidelines for workplace drug screening and the ... Mayo Researchers Examine the Effect of Antioxidant ... reduce the risk of cancer and deaths related to ...
Cached Biology News:Skin care: new research into scar-free healing 2DNA variations signal lupus risk 2DNA variations signal lupus risk 3Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
... The Dyad Disciple thermal cycler is ... It may also be operated independently, using ... variety of interchangeable Alpha units (sample-holder, heat-pump ... well as the Chromo4 real-time detector. Peltier ...
...
I-Ab MHC Class II...
MHC II (HLA-DP)...
Biology Products: